# | Title | Journal | Year | Citations |
---|
1 | Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer | JAMA Oncology | 2018 | 388 |
2 | Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients | Clinical Cancer Research | 2018 | 357 |
3 | Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study | Cancer Cell | 2021 | 99 |
4 | Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study | Journal of Clinical Oncology | 2022 | 97 |
5 | Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial | Journal of Thoracic Oncology | 2020 | 85 |
6 | Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1 | Genome Medicine | 2020 | 81 |
7 | Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy | Clinical Cancer Research | 2021 | 79 |
8 | Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial | Journal of Thoracic Oncology | 2021 | 72 |
9 | Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial | Nature Medicine | 2021 | 65 |
10 | Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial | Annals of Oncology | 2014 | 64 |
11 | The characteristics of ctDNA reveal the high complexity in matching the corresponding tumor tissues | BMC Cancer | 2018 | 59 |
12 | MicroRNA 543 suppresses breast cancer cell proliferation, blocks cell cycle and induces cell apoptosis via direct targeting of ERK/MAPK | OncoTargets and Therapy | 2017 | 49 |
13 | Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer | Investigational New Drugs | 2018 | 42 |
14 | Prevalence and clinical significance of pathogenic germline BRCA1/2 mutations in Chinese non-small cell lung cancer patients | Cancer Biology and Medicine | 2019 | 36 |
15 | A proposal for a new staging system for extranodal natural killer T-cell lymphoma: a multicenter study from China and Asia Lymphoma Study Group | Leukemia | 2020 | 35 |
16 | The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial | Translational Lung Cancer Research | 2019 | 27 |
17 | Association Between RET Fusions and Efficacy of Pemetrexed-based Chemotherapy for Patients With Advanced NSCLC in China: A Multicenter Retrospective Study | Clinical Lung Cancer | 2020 | 23 |
18 | Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population | Lung Cancer | 2020 | 23 |
19 | Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first‐line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open‐label, parallel controlled clinical study | Cancer Communications | 2022 | 22 |
20 | Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy | American Journal of Clinical Oncology: Cancer Clinical Trials | 2019 | 21 |
21 | <p>Frequency, clinical features and differential response to therapy of concurrent <em>ALK/EGFR</em> alterations in Chinese lung cancer patients</p> | Drug Design, Development and Therapy | 2019 | 18 |
22 | Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter study | Translational Lung Cancer Research | 2020 | 18 |
23 | The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study | Cancer Immunology, Immunotherapy | 2022 | 18 |
24 | Irinotecan plus S‐1 versus S‐1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open‐labeled phase 3 trial | Cancer Communications | 2019 | 17 |
25 | Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers | Lung Cancer | 2020 | 17 |
26 | Targeting ALK Rearrangements in NSCLC: Current State of the Art | Frontiers in Oncology | 2022 | 15 |
27 | Clinicopathologic profiling and oncologic outcomes of secretory carcinoma of the breast | Scientific Reports | 2021 | 12 |
28 | HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial | | 2020 | 11 |
29 | Novel AMBRA1-ALK fusion identified by next-generation sequencing in advanced gallbladder cancer responds to crizotinib: a case report | Annals of Translational Medicine | 2020 | 11 |
30 | Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non–Small Cell Lung Cancer After Second-Line Treatment Failure | JAMA Network Open | 2020 | 11 |
31 | Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer | Annals of Translational Medicine | 2022 | 11 |
32 | p63 expression is a prognostic factor in colorectal cancer | International Journal of Biological Markers | 2012 | 10 |
33 | Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC | BMC Medicine | 2021 | 10 |
34 | D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients With NSCLC: Phase 1 Study Results | Journal of Thoracic Oncology | 2023 | 10 |
35 | Interleukin-13 +2044 G/A and +1923C/T polymorphisms are associated with asthma susceptibility in Asians | Medicine (United States) | 2017 | 9 |
36 | Hepatic veno-occlusive disease related to Gynura segetum | Medicine (United States) | 2018 | 9 |
37 | LBA16 Dalpiciclib plus letrozole or anastrozole as first-line treatment for HR+/HER2- advanced breast cancer (DAWNA-2): A phase III trial | Annals of Oncology | 2022 | 9 |
38 | Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER ‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients | Cancer Medicine | 2022 | 8 |
39 | <p>The Multifunction Of miR-218-5p-Cx43 Axis In Breast Cancer</p> | OncoTargets and Therapy | 2019 | 7 |
40 | A prognostic index for nasal‐type early‐stage extranodal natural killer/T‐cell lymphoma: A multicenter study | American Journal of Hematology | 2019 | 7 |
41 | Screening of important lncRNAs associated with the prognosis of lung adenocarcinoma, based on integrated bioinformatics analysis | Molecular Medicine Reports | 2019 | 7 |
42 | Pyrotinib plus capecitabine for HER2-positive metastatic breast cancer patients with brain metastases (PERMEATE): A multicenter, single-arm phase II study. | Journal of Clinical Oncology | 2021 | 7 |
43 | Dalpiciclib versus placebo plus fulvestrant in HR+/HER2- advanced breast cancer that relapsed or progressed on previous endocrine therapy (DAWNA-1): A multicenter, randomized, phase 3 study. | Journal of Clinical Oncology | 2021 | 7 |
44 | Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial | JTO Clinical and Research Reports | 2022 | 7 |
45 | Efficacy and safety of recombinant human lymphotoxin‐α derivative with cisplatin and fluorouracil in patients with metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open‐label, controlled, phase 2b trial | Cancer | 2017 | 6 |
46 | Correlation of plasma erlotinib trough concentration with skin rash in Chinese NSCLC patients harboring exon 19 deletion mutation | Cancer Chemotherapy and Pharmacology | 2018 | 6 |
47 | Tyrosine kinase inhibitor acquired resistance mechanism alternates between EGFR and ALK in a lung adenocarcinoma patient | Thoracic Cancer | 2019 | 6 |
48 | Anticancer drug R&D landscape in China | Journal of Hematology and Oncology | 2020 | 6 |
49 | Utilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinoma | Theranostics | 2021 | 6 |
50 | A pharmacokinetic and safety study of a fixed oral dose of enzastaurin HCl in native Chinese patients with refractory solid tumors and lymphoma | Oncotarget | 2016 | 6 |